Australia's most trusted
source of pharma news
Friday, 08 August 2025
Posted 8 August 2025 AM
AbbVie’s JAK inhibitor Rinvoq has produced some outstanding results in a phase 3 trial evaluating it for the treatment of alopecia.
A 15mg dose, of Rinvoq helped 44.6 per cent of of adult and adolescent patients with severe alopecia areata (AA) achieve 80 per cent or more scalp hair coverage after 24 weeks in study 2 of the phase 3 UP-AA trial, AbbVie reported.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.